Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.
Jhong-Ru HuangChung-Wei ChouHeng-Sheng ChaoPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Given that the ALK inhibitors are the treatment of choice for advanced lung cancer patients with ALK rearrangement. Our report demonstrated the potential feasibility of alectinib re-use in cases of severe druginduced ILD.